Determination of five potential genotoxic impurities in dalfampridine using liquid chromatography
- 1 January 2017
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 133, 27-31
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A stability indicating simultaneous dual wavelength UV–HPLC method for the determination of potential impurities in fampridine active pharmaceutical ingredientJournal of Pharmaceutical and Biomedical Analysis, 2012
- Genotoxic Impurities: A Regulatory Toxicology Commentary on Recent Articles in Organic Process Research & DevelopmentOrganic Process Research & Development, 2011
- Recent advances in trace analysis of pharmaceutical genotoxic impuritiesJournal of Pharmaceutical and Biomedical Analysis, 2010
- Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trialClinical Therapeutics, 2009
- Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up studyClinical Therapeutics, 2009
- Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile studyJournal of Pharmaceutical and Biomedical Analysis, 2008
- Toxicological overview of impurities in pharmaceutical products☆Advanced Drug Delivery Reviews, 2007
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityRegulatory Toxicology and Pharmacology, 2006
- Carcinogenicity categorization of chemicals—new aspects to be considered in a European perspectiveToxicology Letters, 2004
- Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord injury 11A commercial party with a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit on the author or 1 or more of the authors.Archives of Physical Medicine and Rehabilitation, 2004